The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves ...

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure ...